Targeted agents: management of dermatologic toxicities

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Targeted cancer therapies, including epidermal growth factor receptor (EGFR) inhibitors, BRAF, and mTOR inhibitors, are associated with significant cutaneous toxicity.
• Dermatologic side effects are a common and prominent concern in patients undergoing treatment with these agents.

Discussion:

• Dr. Barbara Burtness highlighted common skin complications from targeted therapies at the NCCN 19th Annual Conference.
• Strategies for managing skin toxicities include prophylactic and reactive approaches, emphasizing local measures for quality of life.
• Key interventions involve topical and oral antibiotics and topical steroids to address infections and cosmetic issues.

Key Insights:

• Cutaneous toxicities from targeted therapies require proactive and reactive management strategies.
• Improving skin complications is crucial for patient quality of life and adherence to cancer treatment.
• Early intervention with antibiotics and steroids can effectively manage common dermatologic side effects.

Outlook:

• Further research into optimizing the management of therapy-induced skin conditions is warranted.
• Developing standardized protocols for managing cutaneous side effects can improve patient outcomes.
• Continued focus on supportive care is essential to minimize treatment interruptions due to skin toxicity.